Hikma To Expand Partnership With Arecor; Adds Ready-to-administer Injectable Product

(RTTNews) - Hikma Pharmaceuticals Plc (HIK, HIK.L) and Arecor have entered into an agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc. The product is being developed using Arecor's drug formulation technology platform Arestat. Hikma will seek approval for the product under the 505(b)(2) regulatory pathway, with filing expected in 2023.

Arecor will receive an upfront payment and further payments on the achievement of development, regulatory and commercial milestones. Hikma will be responsible for the manufacture and commercialisation of the product.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More